Disease-associated protein
CA 2443345 C · Owner: Mohand-Said, Saddek · Inventors: Hicks, David; Leveillard, Thierry; Mohand-Said, Saddek
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
Disclosed are methods and compositions for early diagnosis monitoring and , treatment of retinal dystrophy age -related macular degeneration, Bardet- Biedel syndrome, Bassen-kornzweig syndrome best disease, chroidema, gyrate , atrophy congenital amourosis, refsun syndrome, stargardt disease and Usher syndrome. In particular, the invention relates to a protein termed 2Rdcvf1," , that is differentially transcribed and expressed in subjects suffering from retinal dystrophies and the like, such as retinal dystrophy and age -related macular degeneration compared with non- sufferers antibodies which recongnize , this protein and methods for diagnosing such conditions.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed April 5, 2002 and granted December 4, 2012. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended April 5, 2022.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by April 5, 2024.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.